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Background: In 2010, WHO revised guidelines to recommend testing all suspected malaria cases prior to
treatment. Yet, evidence to assess programmes is largely derived from limited facility settings in a limited number
of countries. National surveys from 12 sub-Saharan African countries were used to examine the effect of diagnostic
testing on medicines used by febrile children under five years at the population level, including stratification by
malaria risk, transmission season, source of care, symptoms, and age.
Methods: Data were compiled from 12 Demographic and Health Surveys in 2010–2012 that reported fever
prevalence, diagnostic test and medicine use, and socio-economic covariates (n = 16,323 febrile under-fives taken
to care). Mixed-effects logistic regression models quantified the influence of diagnostic testing on three outcomes
(artemisinin combination therapy (ACT), any anti-malarial or any antibiotic use) after adjusting for data clustering
and confounding covariates. For each outcome, interactions between diagnostic testing and the following covariates
were separately tested: malaria risk, season, source of care, symptoms, and age. A multiple case study design was
used to understand varying results across selected countries and sub-national groups, which drew on programme
documents, published research and expert consultations. A descriptive typology of plausible explanations for
quantitative results was derived from a cross-case synthesis.
Results: Significant variability was found in the effect of diagnostic testing on ACT use across countries (e.g., Uganda
OR: 0.84, 95% CI: 0.66-1.06; Mozambique OR: 3.54, 95% CI: 2.33-5.39). Four main themes emerged to explain results:
available diagnostics and medicines; quality of care; care-seeking behaviour; and, malaria epidemiology.
Conclusions: Significant country variation was found in the effect of diagnostic testing on paediatric fever
treatment at the population level, and qualitative results suggest the impact of diagnostic scale-up on treatment
practices may not be straightforward in routine conditions given contextual factors (e.g., access to care, treatment-seeking
behaviour or supply stock-outs). Despite limitations, quantitative results could help identify countries (e.g., Mozambique)
or issues (e.g., malaria risk) where facility-based research or programme attention may be warranted. The mixed-methods
approach triangulates different evidence to potentially provide a standard framework to assess routine programmes
across countries or over time to fill critical evidence gaps.
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In 2010, the World Health Organization (WHO) revised
guidelines to recommend diagnosis of all suspected mal-
aria cases and treatment based on test results [1], which
could greatly improve malaria surveillance, rational drug
use and quality fever management [2]. National malaria
control programmes are now investing in wide-scale
provision of malaria rapid diagnostic tests (RDT) in
order to achieve these desired outcomes [3].
Yet, evidence to date shows mixed programme success
[4]. While most studies generally indicate a reduction in
anti-malarial treatment after RDT introduction [5-8],
several also indicate frequent anti-malarial prescriptions
despite a negative test result [9-12]. In studies where
first-line malaria treatment (artemisinin-based combin-
ation therapy (ACT)) was largely restricted to positive
cases [13-16], some research shows widespread prescrip-
tions of other anti-malarial [14,17] or antibiotic [13,15]
drugs to test-negative patients and not according to
established guidelines [18].
However, research has largely been derived from limited
health facility settings in a limited number of countries
within well-established public health research centres,
notably Kenya, Malawi, Tanzania, Uganda, and Zambia
[4]. Evidence is limited for most other countries despite,
in many cases, comparable RDT investments [19]. While
a few countries have conducted national facility studies
to examine case management practices across different
sub-national contexts [9,20,21], there remains limited
understanding of how these practices may differ across
key sub-national groups, notably by malaria risk [6,7,12].
Moreover, facility-based studies by their nature do not
provide evidence from community settings where paediat-
ric fevers are commonly treated and, perhaps in the
future, will be increasingly tested as well [22,23]. There is
also limited evidence from routine conditions compared
to controlled study trial contexts [24], and how broader
programme contexts could influence test-based case
management practices (e.g., care-seeking behaviour) [25].
National, population-based, cross-sectional surveys are
routinely implemented in sub-Saharan African countries
and could be further analysed to provide additional
evidence for programmes. Since 2010, these surveys have
collected comparable data on malaria diagnostic test
use by febrile children under five years [26], although
caregivers are not asked about their child’s test result.
It is therefore not possible to examine (in)appropriate
test-based treatment using these data.
Nevertheless, it is reasonable to expect diagnostic testing
to reduce overall ACT use for paediatric fevers at the
population level since only a sub-set of tested patients (e.g.,
test-positive cases) should receive malaria treatment com-
pared to presumptively treating untested cases. Similarly,
diagnostic testing could also reduce any anti-malarial use,although reductions may be less marked if second-line
treatment is prescribed to test-negative cases [14,17] or
caregivers self-treat with other anti-malarial drugs in
community settings [25]. It is also plausible that lowered
anti-malarial use among tested paediatric fevers could
be met with higher antibiotic treatment as an alternative
therapy [13,15]. Finally, such drug use changes could be
more pronounced among populations with lower frac-
tions of malaria-attributable fevers or where there may
be different financial barriers for treatment (e.g., public/
private sectors) [22].
In this paper, the effect of diagnostic testing on anti-
malarial and antibiotic use among febrile children less
than five years was examined in 12 sub-Saharan African
countries in 2010–2012, including stratification by malaria
risk, transmission season, source of care, child’s age, and
symptoms. Given unexpected results, a post-hoc analysis
using a multiple case study design was employed to
understand the complex phenomena driving results in
select countries. Such mixed-methods approaches are
valuable in health services research to evaluate interven-
tions or answer complex questions [27].
Methods
This study uses a mixed-methods approach to analyse
the effect of diagnostic testing on paediatric fever treat-
ment at the population level across multiple countries,
and to plausibly explain findings in select countries.
Data sources
National, population-based, cross-sectional surveys con-
ducted in sub-Saharan Africa between 1 January, 2008
and 1 May, 2014 were systematically reviewed for inclu-
sion in this study (Figure 1). All datasets were included
if they measured outcome and explanatory covariates as
described below. Twelve Demographic and Health Surveys
(DHS) in 2010–2012 met inclusion criteria (Table 1).
Survey methods are described elsewhere, including proce-
dures for obtaining ethical approval and written informed
consent from participants [28].
Outcomes
Paediatric fever treatment was measured by asking care-
givers of children under five with reported fever in the
previous two weeks if “At any time during the illness did
(name) take any drugs, and if so, what drugs did (name)
take?” Response categories included anti-malarial drugs
(by type), antibiotic drugs (pill/syrup or injection) or
other medicines. Multiple responses were allowed and
sick children receiving dual treatment were categorized
as having positive outcomes for both responses. Anti-
malarial medicines reported include ACT, chloroquine,
sulphadoxine-pyrimethamine (SP)/Fansidar, quinine and
other country-specific brands. Any anti-malarial use
DHS, MICS, MIS and ACT Watch survey conducted
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12 DHS datasets met inclusion criteria
(Table 1)
Other explanatory covariates
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available for link malaria risk and 
transmission season estimates to 
datasets (n = 12)
Figure 1 Flow chart for inclusion criteria of country datasets.
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treat the fever illness while ACT use referred to that
treatment alone. Any antibiotic use referred to either
pill/syrup or injection antibiotic drugs, and was not
further disaggregated by type in response categories.
Main explanatory predictor
Malaria diagnostic test use was measured by asking
caregivers of febrile children if “At any time during the
illness did (name) have blood taken from his/her finger
or heel for testing?” This question was assumed to refer
to either microscopy or RDT. The questionnaire did not
explicitly record where testing and treatment occurred,
nor if these interventions were received together. 812(5%) children across 12 countries taken to multiple
sources were excluded in order to assume that both
interventions were provided at the same source.
Other explanatory covariates
The model included other covariates associated with
both diagnosis and treatment, which were grouped into
individual, household and community factors [29-31].
Individual factors included child’s sex and age (0–5,
6–11, 12–23, 24–35, 36–47, 48–59 months), maternal
age (15–24, 25–29, 30–34, 35–39, 40–49 years) and edu-
cation (none, primary or at least secondary), and symp-
toms (fever alone, fever with cough, and fever with
cough and rapid breaths). The latter covariate was also




















Benin DHS 2011-2012 Total 620 20.0 (16.1-24.0) 48.0 (43.2-52.9) 17.5 (14.0-21.0) 28.6 (24.5-32.6) 2011
Tested 124 - 59.9 (48.3-71.5) 22.1 (14.0-30.3) 30.8 (21.3-40.2)
Not tested 492 - 44.8 (39.8-49.7) 16.0 (12.3-19.7) 27.9 (23.2-32.5)
Burkina Faso DHS 2010-2011 Total 1,823 7.7 (6.1-9.2) 48.0 (44.8-51.1) 12.5 (10.6-14.4) 44.0 (40.9-47.1) 2009
Tested 140 - 61.1 (51.9-70.3) 16.9 (10.5-23.3) 44.2 (35.0-53.4)
Not tested 1,671 - 46.8 (43.6-50.1) 12.1 (10.1-14.1) 43.8 (40.6-47.0)
Burundi DHS 2010-2011 Total 1,432 36.9 (33.4-40.4) 25.9 (22.8-29.0) 18.0 (15.2-20.9) 54.6 (50.7-58.5) 2007
Tested 528 - 38.3 (32.5-44.0) 24.9 (19.3-30.6) 48.8 (42.7-54.9)
Not tested 895 - 18.8 (15.7-21.9) 14.1 (11.1-17.0) 58.1 (53.9-62.2)
Cote d’Ivoire DHS 2011-2012 Total 965 13.6 (10.7-16.4) 22.7 (18.8-26.7) 3.3 (1.7-4.9) 34.6 (30.3-38.9) -
Tested 131 - 42.4 (32.1-52.7) 9.2 (3.3-15.1) 45.9 (35.9-56.0)
Not tested 821 - 19.2 (15.3-23.2) 2.4 (0.7-4.1) 33.0 (28.4-37.6)
Gabon DHS 2012 Total 738 16.8 (11.3-22.3) 26.2 (20.0-32.4) 10.6 (6.9-14.4) 59.0 (51.5-66.5) 2009
Tested 124 - 32.9 (20.5-45.3) 8.6 (3.6-13.5) 51.2 (37.6-64.8)
Not tested 596 - 25.0 (17.6-32.3) 10.8 (5.9-15.6) 60.9 (53.2-68.6)
Guinea DHS 2012 Total 931 12.7 (9.8-15.6) 44.3 (39.9-48.7) 2.2 (1.0-3.4) 40.6 (35.9-45.2) 2010
Tested 118 - 53.0 (40.9-65.0) 4.1 (0.7-7.5) 54.6 (43.7-65.4)
Not tested 808 - 43.0 (38.4-47.7) 1.9 (0.6-3.2) 38.3 (33.5-43.1)
Malawi DHS 2010 Total 4,337 21.4 (19.2-23.6) 55.0 (52.5-57.4) 46.5 (44.0-49.1) 29.6 (27.6-31.7) 2011
Tested 928 - 64.2 (59.1-69.3) 50.6 (45.3-55.9) 33.8 (29.2-38.5)
Not tested 3,363 - 52.6 (50.1-55.1) 45.6 (43.0-48.1) 28.5 (26.3-30.7)
Mozambique DHS 2011 Total 888 43.4 (38.8-48.1) 41.8 (37.1-46.5) 25.3 (20.7-29.9) 12.0 (9.6-14.5) 2009
Tested 386 - 55.5 (48.9-62.0) 39.7 (32.5-46.9) 12.8 (9.0-16.6)
Not tested 502 - 31.3 (25.9-36.8) 14.3 (10.2-18.3) 11.4 (8.0-14.8)
Rwanda DHS 2010-2011 Total 657 36.6 (32.6-40.6) 20.4 (17.3-23.5) 19.6 (16.5-22.7) 49.1 (45.0-53.2) 2009
Tested 240 - 20.4 (15.5-25.3) 19.9 (15.1-24.7) 65.4 (59.2-71.6)
Not tested 413 - 20.6 (16.5-24.7) 19.6 (15.6-23.6) 39.5 (34.4-44.5)
Senegal DHS 2010-2011 Total 1,275 14.9 (11.9-17.9) 14.1 (10.5-17.7) 5.5 (3.1-8.0) 43.0 (37.6-48.3) 2007
Tested 190 - 20.4 (11.2-29.6) 8.8 (3.6-13.9) 51.9 (40.1-63.6)
Not tested 1,078 - 13.0 (9.4-16.7) 4.9 (2.3-7.6) 41.5 (36.2-46.8)
Uganda DHS 2011 Total 2,440 28.6 (25.5-31.6) 69.9 (67.0-72.7) 47.5 (43.8-51.1) 35.3 (32.3-38.2) 1997
Tested 697 - 76.4 (71.9-80.8) 52.7 (47.2-58.1) 40.9 (35.4-46.5)
Not tested 1,726 - 67.6 (64.1-71.1) 45.5 (41.3-49.7) 33.1 (29.7-36.5)
Zimbabwe DHS 2010-2011 Total 217 12.6 (7.8-17.5) 5.0 (1.3-8.7) 2.6 (0.2-5.0) 38.8 (31.9-45.8) 2008
Tested 27 - 20.5 (3.8-37.1) 10.9 (−2.0-23.8) 30.2 (12.1-48.3)
Not tested 189 - 2.8 (0.3-5.2) 1.4 (−0.6-3.5) 40.1 (32.7-47.5)
National point estimates were tabulated using sample weights pre-specified in datasets. Standard error estimation accounted for data clustering in survey designs.
aChildren under five years old reportedly having fever in the two weeks prior to the interview and taken to any source of care.
bChildren under five years old with fever in the previous two weeks taken to any care and reportedly receiving a finger or heel stick for testing.
cChildren under five years old with fever in the previous two weeks taken to any care and reportedly receiving any anti-malarial drug of any type.
dChildren under five years old with fever in the previous two weeks taken to any care and reportedly receiving ACT.
eChildren under five years old with fever in the previous two weeks taken to any care and reportedly receiving any antibiotic drug of any type.
f[60] Refers to year national policy changed to recommend parasitological diagnosis in patients of all ages prior to treatment.
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sured in surveys, and multiple symptoms were assumed
to reflect more severe cases [32].
Household factors included wealth and size, care-
seeking behaviour, and access to testing and care. A
wealth index was pre-specified in datasets and described
elsewhere [33]. Household size was categorized as one
to four, five to eight, nine to 12, and 13 or more house-
hold members [34]. Care-seeking behaviour was based
on caregiver reports of where care was sought for the
sick child, and was separately coded by level of care
(hospital, non-hospital formal medical, community
health worker (CHW), pharmacy, and other) and sector
(public, private) [35,36]. Access to testing and care was
based on caregivers’ perceptions that money or distance
is a “big problem” or “not a big problem” to seeking
medical advice or treatment. These two covariates, along
with child health card possession, were used to attempt
to proxy attendance at a facility stocked with both drugs
and diagnostic tests, which is known to influence case
management decisions but is not directly measured in
surveys.
Community factors included residence (urban/rural),
malaria risk and transmission season. Malaria Atlas Pro-
ject malaria endemicity estimates were linked to datasets
through geocoded primary sampling units (PSUs) [37].
All individual observations were assigned their PSU-
level malaria risk value and categorized as malaria-free,
unstable, low (PfPR2–10 < 5%), moderate (PfPR2–10 5%-40%),
and high (PfPR2–10 > 40%) stable endemic transmission.
Each observation was also classified as occurring during or
outside the peak malaria transmission season by comparing
each observation’s PSU location and interview date with
seasonality maps produced by the Mapping Malaria Risk
in Africa (MARA) project [38].
Among 16,323 surveyed febrile children under five
taken to care in 12 countries, 17 had missing values for
the outcomes, 24 for diagnostic test use, 309 for malaria
endemicity and transmission season, seven for health
card and one for maternal education. List-wise deletion
was used to exclude these observations.
Statistical analysis
Mixed-effects logistic regression models quantified the
influence of diagnostic testing on paediatric fever treat-
ment among children taken to care in each country
dataset. The binary outcomes analysed were: (1) ACT
use; (2) any anti-malarial use; and, (3) any antibiotic use.
All covariates were included as categorical fixed effects
(first-level) nested within PSUs (second-level), and nor-
mal distribution of the random effects was assumed.
Crude odds ratios for the main covariate were initially
estimated for its effect on each outcome, and were sub-
sequently adjusted for the effect of all covariates. Foreach outcome, interactions between diagnostic testing
and the following covariates were separately tested: mal-
aria risk, season, source of care, age, and symptoms. If
there was evidence of an interaction, final models were
stratified accordingly to explore results. The level of
statistical significance was set to 0.05. National point
estimates were tabulated using sample weights to ac-
count for unequal probabilities of selection in order to
generate nationally representative weighted percentages.
Standard error estimation accounted for data clustering
in the complex survey design. Stata 12 (STATA Corp,
College Station, TX) was used for all analyses.
Case study methods
A multiple case study design was employed to help under-
stand results in selected countries and drew on published
research, programme documents and expert consultations
[27]. Country selection was based on the following cri-
teria: (1) contrasting quantitative results; (2) high ACT
coverage; and, (3) available research or programme docu-
ments. Benin, Burundi, Malawi, Mozambique, Rwanda
and Uganda were selected for case studies.
A comprehensive literature review identified published
articles on malaria diagnosis and treatment practices in
these countries. Benin and Malawi had national facility
studies conducted around the same time to help explain
results [9,20], while Uganda, Malawi and Mozambique had
relevant research to support case studies [12,16,39,40].
National malaria strategic plans for Malawi, Mozambique
and Uganda were made available for this study [41-43], and
all six countries had US President’s Malaria Initiative
operational plans [44]. These materials were reviewed to
identify potential explanations for quantitative findings,
inform the topic guide used in expert consultations,
and cross-reference interview information to confirm
conclusions.
For expert consultations, seven respondents were pur-
posively selected based on their country programme
knowledge and advanced research training. Five infor-
mants were identified and contacted by study authors
(EWJ, SP) while two others were introduced by initial re-
spondents using snowballing and convenience sampling
techniques. Participants included university researchers,
paediatricians and epidemiologists with expert knowledge
of national malaria control programmes. Prior to involve-
ment, respondents were given detailed information about
the study’s objectives, methods and full quantitative re-
sults. Respondents were also invited to review case studies
as well as the final manuscript.
Interviews were based on a semi-structured topic guide
that focused on the plausibility of results, programme ex-
planations and perceived value of findings as additional
programme evidence. Specific themes included: RDT scale-
up status; availability of diagnostics and medicines; stock-
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care-seeking behaviour; and, malaria epidemiology.
The lead author (EWJ) conducted seven interviews in
English via Skype or in person during July-September
2014 (one for each country; two for Benin) each lasting
about one hour. Extensive written notes were taken dur-
ing interviews and transcribed after discussions. Explan-
ation building leading to a cross-case synthesis was the
overall analytic strategy [45]. This approach emphasizes
defining and testing rival explanations as part of the
design, and compiling data from multiple sources to
triangulate evidence and evaluate rival interpretations
[27]. Thematic analysis identified dominant themes
within each case [46]. All transcripts were read multiple
times by the lead author to establish preliminary codes
and create categories to describe response patterns.
Matrices helped to visually examine codes in order
to generate within-case themes, and to subsequently
compare and revise themes across countries. This led to
a typology of plausible explanations for quantitative re-
sults for the six countries.
Results
Quantitative results
16,323 children under five years had fever in the previ-
ous two weeks and were taken to any care across 12
countries (Table 1). 3,633 of these children received a
diagnostic test with national coverage ranging between
8% and 43%. Across the 12 countries, 7,154 children
received any anti-malarial drug, 4,332 received ACT, and
6,115 received any antibiotic drug according to caregiver
reports.
Table 2 presents the association between the main
predictor and the three outcomes (ACT use, any anti-
malarial use and any antibiotic use) in each of the 12
countries. Results for other covariates included in the
final country models are provided in additional files
(Additional file 1 and Additional file 2). These results
indicate that no studied country had significantly re-
duced odds of malaria treatment for tested paediatric
fevers compared to untested, which is the opposite of
the stated hypothesis. However, there was variability in
the effect of diagnostic testing on paediatric fever treat-
ment across countries.
ACT use
In six countries, tested paediatric fevers had significantly
higher ACT use odds compared to untested cases
according to caregiver reports (Burundi, Côte d’Ivoire,
Gabon, Mozambique, Senegal, Zimbabwe), although
Zimbabwe and Côte d’Ivoire results should be inter-
preted with caution due to few observations and positive
outcomes. Burundi and Mozambique were among the
countries with highest ACT use odds for tested paediatricfevers compared to untested ones (Burundi OR: 2.78, 95%
CI: 1.81-4.27; Mozambique OR: 3.54, 95% CI: 2.33-5.39).
In contrast, Rwanda and Uganda had relatively lower odds
of ACT use associated with testing (Rwanda OR: 0.88,
95% CI: 0.51-1.51; Uganda OR: 0.84, 95% CI: 0.66-1.06).
Any anti-malarial use
Six countries demonstrated significantly higher anti-
malarial use odds associated with reported testing
(Burundi, Côte d’Ivoire, Gabon, Malawi, Mozambique,
Senegal). There was also variability in results across
countries as exemplified by Burundi (OR: 3.71, 95% CI:
2.63-5.25) and Mozambique (OR: 2.79, 95% CI: 1.92-4.05)
compared to Rwanda (OR: 0.83, 95% CI: 0.48-1.44) and
Uganda (1.24, 95% CI: 0.96-1.61).
Any antibiotic use
Only Rwanda and Uganda had significantly higher anti-
biotic use odds associated with diagnostic testing
(Rwanda OR: 2.95, 95% CI: 1.82-4.79; Uganda OR: 1.37,
95% CI: 1.09-1.72) while Burundi had significantly lower
antibiotic use odds for tested paediatric fevers compared
to untested cases (OR: 0.53, 95% CI: 0.40-0.72).
Sub-national results
Table 3 suggests differences in the effect of diagnostic
testing on paediatric fever treatment within some coun-
tries by malaria risk, source of care and symptoms.
There was no evidence of interactions for other investi-
gated variables (season, age) due in part to insufficient
power to detect such differences.
Malaria risk
In four countries (Benin, Burundi, Malawi, Uganda), data
suggest higher-risk areas had higher malaria treatment
odds associated with diagnostic testing compared to
lower-risk areas, and the opposite for antibiotic use. In
Uganda, moderate-risk areas had significantly reduced
ACT use odds for tested compared to untested cases
(OR: 0.67, 95% CI: 0.46-0.98) and significantly higher
antibiotic use odds associated with testing (OR: 1.68,
95% CI: 1.12-2.52), while there was a negligible differ-
ence in high-risk areas. In Benin and Malawi, tested
paediatric fevers in high-risk areas had significantly
higher anti-malarial use odds compared to untested
cases (Benin OR: 2.30, 95% CI: 1.10-4.82; Malawi OR:
1.63, 95% CI: 1.26-2.11), while this difference was negli-
gible in moderate-risk areas. In Burundi, antibiotic treat-
ment odds was significantly higher in low-risk areas for
tested compared to untested cases (OR: 6.75, 95% CI:
1.30-35.00), although this strong effect should be inter-
preted with caution. Conversely, there was significantly
lower antibiotic use odds associated with testing in
moderate-risk settings (OR: 0.44, 95% CI: 0.32-0.60).
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COR (95% CI) AOR (95% CI) p value COR (95% CI) AOR (95% CI) p value COR (95% CI) AOR (95% CI) p value
Benin 620 298 2.61 (1.51-4.51) 1.65 (0.92-2.98) 0.096 109 2.37 (1.20-4.70) 1.96 (0.91-4.19) 0.084 177 1.83 (1.06-3.17) 1.15 (0.64-2.08) 0.636
Burkina Faso 1,823 875 2.08 (1.39-3.11) 1.32 (0.84-2.05) 0.225 228 1.64 (0.99-2.71) 1.45 (0.84-2.52) 0.180 803 1.22 (0.82-1.81) 0.89 (0.57-1.40) 0.616
Burundi 1,432 371 3.62 (2.64-4.96) 3.71 (2.63-5.25) <0.001 258 2.62 (1.79-3.83) 2.78 (1.81-4.27) <0.001 782 0.62 (0.47-0.81) 0.53 (0.40-0.72) <0.001
Cote d’Ivoire* 965 220 3.29 (2.05-5.25) 1.89 (1.14-3.13) 0.013 32 7.09 (2.45-20.54) 16.83 (1.03-276.13) 0.048 334 1.99 (1.31-3.01) 1.08 (0.68-1.74) 0.737
Gabon 738 194 2.25 (1.40-3.61) 2.00 (1.16-3.44) 0.013 78 2.74 (1.45-5.16) 2.45 (1.13-5.33) 0.024 436 0.88 (0.58-1.35) 0.84 (0.52-1.35) 0.467
Guinea* 931 412 1.70 (1.08-2.67) 1.28 (0.78-2.11) 0.330 20 4.29 (1.25-14.68) 2.42 (0.43-13.68) 0.319 378 1.76 (1.11-2.78) 1.05 (0.63-1.75) 0.862
Malawi 4,337 2,384 1.65 (1.40-1.94) 1.34 (1.11-1.61) 0.002 2,019 1.26 (1.07-1.48) 1.12 (0.94-1.34) 0.206 1,285 1.12 (0.94-1.33) 1.00 (0.82-1.22) 1.000
Mozambique 888 371 2.85 (2.02-4.02) 2.79 (1.92-4.05) <0.001 225 3.65 (2.45-5.42) 3.54 (2.33-5.39) <0.001 107 1.04 (0.67-1.61) 1.01 (0.64-1.59) 0.966
Rwanda* 657 134 0.93 (0.57-1.52) 0.83 (0.48-1.44) 0.506 129 0.96 (0.59-1.56) 0.88 (0.51-1.51) 0.633 322 3.70 (2.38-5.74) 2.95 (1.82-4.79) <0.001
Senegal 1,275 180 1.75 (1.11-2.75) 1.69 (1.04-2.76) 0.036 70 2.54 (1.24-5.19) 2.99 (1.32-6.79) 0.009 547 1.90 (1.27-2.85) 1.50 (0.97-2.31) 0.070
Uganda 2,440 1,704 1.50 (1.19-1.89) 1.24 (0.96-1.61) 0.097 1,158 1.13 (0.92-1.39) 0.84 (0.66-1.06) 0.133 860 1.45 (1.18-1.78) 1.37 (1.09-1.72) 0.007
Zimbabwe* 217 11 13.23 (1.56-112.52) 170.9 (0.30-98480.04) 0.113 6 12.18 (1.94-76.45) 25.55 (1.69-385.68) 0.019 84 0.62 (0.24-1.60) 0.55 (0.20-1.51) 0.244
CI = confidence interval. AOR = adjusted odds ratio. COR= crude odds ratio. AORs based on mixed-effects logistic regression models in individual country datasets adjusted for data clustering and confounding covariates (malaria en-
demicity; transmission season; public/private source; level of care; child’s age and sex; maternal age and education; residence; household wealth and size; health care access (money); health care access (distance);
symptoms; health card).
*Rwanda’s model does not include the ‘level of care’ covariate due to multi-collinearity with the public/private source covariate. Guinea’s model does not include ‘money or distance as problems accessing care’ covariates. Some










Table 3 Sub-national differences in the effect of diagnostic testing on paediatric fever treatment in studied countries





% with a diagnostic
test (95% CI)
AOR (95% CI) p value
Malaria risk
Benin Any anti-malarial use High risk 403 50.8 (45.3-56.3) 20.0 (16.1-24.4) 2.30 (1.10-4.82) 0.028
Moderate risk 212 41.4 (32.9-50.5) 18.7 (11.9-28.1) 0.32 (0.08-1.29) 0.108
Burundi* Any antibiotic use Moderate risk 1,239 54.0 (49.8-58.2) 37.7 (33.8-41.6) 0.44 (0.32-0.60) <0.001
Low risk 125 57.3 (42.7-71.8) 37.1 (27.2-47.0) 6.75 (1.30-35.00) 0.023
Malawi Any anti-malarial use High risk 1,870 56.9 (53.8-60.1) 19.5 (16.8-22.2) 1.63 (1.26-2.11) <0.001
Moderate risk 2,361 53.2 (49.5-56.9) 22.8 (19.3-26.3) 1.12 (0.85-1.47) 0.410
Uganda ACT use High risk 1,730 46.1 (41.5-50.9) 26.9 (23.3-30.8) 0.95 (0.70-1.28) 0.736
Moderate risk 625 51.6 (46.2-57.1) 34.7 (28.9-41.1) 0.67 (0.46-0.98) 0.040
Any antibiotic use High risk 1,730 36.6 (32.9-40.4) 26.9 (23.3-30.8) 1.24 (0.93-1.65) 0.146
Moderate risk 625 33.0 (28.3-38.1) 34.7 (28.9-41.1) 1.68 (1.12-2.52) 0.012
Source of care
Malawi Any antibiotic use Public 2,978 27.6 (25.2-30.0) 19.3 (17.2-21.4) 0.85 (0.67-1.09) 0.199
Private 1,358 34.0 (30.2-37.8) 26.0 (21.7-30.4) 1.36 (0.95-1.96) 0.097
Rwanda* Any anti-malarial use Public 522 24.4 (20.8-28.4) 40.3 (35.8-44.8) 0.59 (0.31-1.14) 0.119
Private 134 5.0 (2.3-10.8) 22.4 (15.6-31.1) 29.38 (2.25-383.63) 0.010
Symptoms
Benin* Any anti-malarial use Fever alone 380 46.6 (40.9-52.5) 15.5 (11.8-20.1) 0.94 (0.39-2.29) 0.893
Fever, cough,
rapid breaths
239 50.5 (43.1-57.8) 27.2 (21.0-34.5) 5.48 (1.27-23.63) 0.022
Burkina Faso Any anti-malarial use Fever alone 1,253 48.5 (44.9-52.2) 6.9 (5.5-8.6) 2.03 (1.13-3.66) 0.018
Fever, cough,
rapid breaths
570 46.7 (42.0-51.5) 9.5 (6.9-12.8) 0.69 (0.34-1.41) 0.304
Malawi ACT use Fever alone 1,980 51.7 (48.4-54.9) 21.9 (19.3-24.5) 0.87 (0.66-1.13) 0.298
Fever, cough,
rapid breaths
2,355 42.2 (39.1-45.4) 21.0 (18.1-23.9) 1.40 (1.09-1.79) 0.008
Any antibiotic use Fever alone 1,980 18.2 (16.0-20.4) 21.9 (19.3-24.5) 1.46 (1.07-1.99) 0.017
Fever, cough,
rapid breaths
2,355 39.2 (36.2-42.2) 21.0 (18.1-23.9) 0.77 (0.60-1.00) 0.052
Senegal* ACT use Fever alone 527 5.6 (3.3-9.1) 15.1 (11.5-19.6) 75.42 (1.09-5212.78) 0.045
Fever, cough,
rapid breaths
747 5.5 (3.2-9.3) 14.8 (11.1-19.4) 1.69 (0.50-5.73) 0.400
If evidence of an interaction was found (0.05 level) between diagnostic testing and investigated variables (malaria risk, transmission season, age, symptoms,
source of care) within a country, the final model was stratified accordingly and results presented above. CI = confidence interval; AOR = adjusted odds ratio. AORs
are based on mixed-effects logistic regression models for specified strata in each country dataset adjusted for data clustering and confounding covariates (malaria
endemicity; transmission season; public/private source; level of care; child’s age and sex; maternal age and education; residence; household wealth and size; health
care access (money); health care access (distance); symptoms; health card).
*Some results should be interpreted with caution due to few observations and few positive outcomes.
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Attending private sources in Rwanda was associated
with significantly higher anti-malarial treatment odds for
tested paediatric fevers compared to untested ones (OR:
29.38, 95% CI: 2.25-383.63), although this strong effect
should be interpreted with caution. Malawi also had
slightly higher antibiotic treatment odds associated with
testing in the private sector, but this result was non-
significant.Symptoms
There was less consistency in sub-national results by re-
ported symptoms. In Benin, tested children with fever
and respiratory symptoms had significantly higher anti-
malarial treatment odds compared to untested cases
(OR: 5.48, 95% CI: 1.27-23.63), while there was no differ-
ence if fever alone was reported. In Malawi, reporting
fever and respiratory symptoms was associated with 1.40
(95% CI: 1.09-1.79) times higher ACT use odds for
Johansson et al. Malaria Journal  (2015) 14:194 Page 9 of 14tested cases compared to untested ones, with a negligible
difference for children with fever alone. Conversely, in
Burkina Faso, tested children having fever alone had
significantly higher malaria treatment odds compared to
untested cases (OR: 2.03, 95% CI: 1.13-3.66), while there
was no difference if fever and respiratory symptoms
were reported.
Case studies
Case study summaries focus on describing relevant
programme features or contextual factors derived from
interviews and document reviews that could help under-
stand quantitative results. Case studies for the six coun-
tries are presented in additional files (Additional file 3)
and were used to inform the cross-case synthesis to
identify common themes across countries and sub-
national groups highlighted below (Table 4).
Available diagnostics and medicines was emphasized
by all respondents as a central issue affecting results.
“Children getting tested are probably at locations that
also have medicines, and those not tested likely have
worse access to ACT. That’s a key issue.” (Benin case
study).
Only Rwanda, Benin and Mozambique had initiated
wide-scale RDT deployment prior to surveys, and in
Rwanda, CHWs used RDT. Data for remaining countries
largely reflects testing by microscopy concentrated at
referral hospitals, except Uganda where health centres
have laboratory services. Weak supply systems could
also reduce availability of diagnostics or medicines,
which further concentrates supplies at hospitals even if
RDT scale-up was previously initiated. In Uganda, micros-
copy services were offered at health centres but with
inconsistent ACT supplies at these facilities around this
time. Rwanda, in contrast, was described as having a
strong logistics system for medicines and diagnostics.
Quality of care may also influence findings if there is
poor test-based case management at sources with both
diagnostics and medicines. Contemporaneous research
in Benin, Malawi and Uganda indicated that about
20-50% of test-negative patients were prescribed malaria
treatment [9,12,20,39] with plausibly worse adherence
for young children [20] and in routine conditions [24]. It
should be noted that only Benin and Malawi results are
based on national-level facility surveys. In Mozambique
and Burundi, test adherence practices were perceived as
poor.
“(In Mozambique) there was little experience with testing
at peripheral facilities at this time (with the lack of
widely available RDT stocks), and poor case management
practices in general.” (Mozambique case study).In Rwanda, adherence practices were seen as compara-
tively good although effect differences across public/pri-
vate sources were attributed to poor practices at the
latter (Table 3).
“The private sector is small and more developed in
Kigali. Clients attending these facilities often expect or
demand certain medicines and some health providers
want to maintain client satisfaction.” (Rwanda case
study).
Care-seeking behaviour was also described as influen-
cing quantitative results, particularly in countries where
drug shops are commonly used to treat sick children or
where there is difficult access to formal care.
“In Benin care-seeking often goes: child has fever, taken
to shop, gets medicines, doesn’t get better, goes to facility
(where finally tested).” (Benin case study).
Caregivers may self-treat sick children at home or in
communities either before or after visiting a facility
where diagnostic testing occurs. This could result in
over-treatment associated with diagnostic testing at the
population level that is unrelated to the quality of care
provided at facilities although attempts were made to ac-
count for this issue in the analysis (see Methods). In
addition, this practice may delay visiting formal pro-
viders such that children are more severely ill once they
reach facilities with diagnostic services, which further in-
creases treatment likelihood. Illness severity was also put
forward to potentially explain effect differences found by
child symptoms in Malawi and Benin (Table 3). Delayed
care-seeking practices are also an important issue for
countries where there is simply difficult access to formal
care, particularly if supplies are concentrated at hospitals.
“(In Burundi) microscopy is basically in hospitals and
healthcare access is difficult - remote, hilly communities.
These results really show poor access to care.” (Burundi
case study).
Malaria epidemiology was also noted to affect results
since the likelihood of malaria infection plausibly influ-
ences diagnosis and treatment practices. Four studied
countries showed effect differences across malaria strata,
which may further support this theory (Table 3).
“There are three main reasons I can think of that
could explain (Mozambique) results: (1) high malaria
prevalence in certain areas even in the dry season (2)
poor case management practices (3) access to testing
and care (rural, bad infrastructure, hard to get tested
and treated).” (Mozambique case study).
Table 4 Descriptive typology of plausible explanations for quantitative results in six countries
Rwanda Uganda Malawi Benin Mozambique Burundi
DHS 2010-2011 DHS 2011 DHS 2010 DHS 2011-2012 DHS 2011 DHS 2010-2011
Outcomes (see Table 2) AOR (any anti-malarial use) 0.83 (0.48-1.44) 1.24 (0.96-1.61) 1.34 (1.11-1.61) 1.65 (0.92-2.98) 2.79 (1.92-4.05) 3.71 (2.63-5.25)
AOR (ACT use) 0.88 (0.51-1.51) 0.84 (0.66-1.06) 1.12 (0.94-1.34) 1.96 (0.91-4.19) 3.54 (2.33-5.39) 2.78 (1.81-4.27)
AOR (any antibiotic use) 2.95 (1.82-4.79) 1.37 (1.09-1.72) 1.00 (0.82-1.22) 1.15 (0.64-2.08) 1.01 (0.64-1.59) 0.53 (0.40-0.72)
Available diagnostics and
medicines
National ACT scale-up initiated Yes Yes Yes Yes Yes Yes
National RDT scale-up initiated Yes No No Yes Yes No
Reported inconsistent RDT supplies No N/A N/A Mixed reports [9,44] Yes N/A
Reported inconsistent ACT supplies No Yes No [20] Yes Yes Yes
Diagnostics at community-level Yes [61] No No No No No
Diagnostics at peripheral facilities Yes Yes* No Yes** Yes** No
Diagnostics at hospitals Yes Yes Yes Yes Yes Yes
Quality of care Diagnostic test adherence (% test-negative
patients prescribed malaria treatment)
Perceived good Poor [30%;48%] [12,39] Poor [20%] [20] Poor [38%] [9] Perceived poor Perceived poor
Care-seeking behaviour Extensive use of informal private sector No Yes [62] No Yes No No












Information summarizes case study discussions and references [41-44] unless otherwise noted. Reported percentages of test-negative patients prescribed malaria treatment refers to all patients and is plausibly higher
for young children and in routine program conditions. Benin and Malawi results based on national-level facility surveys.
*In Uganda, microscopy is available at HC-III and higher-level facilities.
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Overall, findings indicate variability in the effect of diag-
nostic testing on paediatric fever treatment at the popu-
lation level across studied countries in 2010–2012, and
no country demonstrated significant ACT use reductions
associated with testing as hypothesized. Four common
themes emerged to explain varying results: available
diagnostics and medicines; quality of care; care-seeking
behaviour; and, malaria epidemiology.
Indeed, the study hypothesis is implicitly grounded in
an assumption that all febrile children have similar ac-
cess to medicines irrespective of testing status, and that
untested paediatric fevers are presumptively given mal-
aria treatment while only a sub-set of tested ones are
treated (e.g., positive cases). There are numerous reasons
why this hypothesis may not hold in routine programme
conditions, particularly at the outset of new guidelines,
and that significantly different results may be observed
across countries.
One important issue is that countries included in this
analysis had relatively low diagnostic test coverage at the
population level given the early assessment. This low
coverage plausibly indicates that diagnostic services
remained concentrated at higher-level facilities that gen-
erally have better medicine stocks and more severely ill
patients, both of which increase treatment likelihood. In-
deed, available diagnostics and medicines was a main
theme identified in this study to explain varying results
(see Table 4). This is consistent with other research sug-
gesting that access to care is the greatest contributor to
reduced systems effectiveness for malaria case manage-
ment in Zambia [47].
This theme was cited as a main explanation for results
across all case study countries. In Mozambique and
Burundi, for example, diagnostic services were concen-
trated at hospitals at the time of survey fieldwork given
the lack of RDT scale-up (e.g., Burundi) or widespread
RDT stock-outs (e.g., Mozambique). At the same time,
both of these countries experienced ACT shortages at
peripheral clinics such that febrile children attending lo-
cations with diagnostic tests probably had better access
to medicines. General poor access to formal care and
low use of informal providers (e.g., drug shops) in these
countries may have further compounded the vast under-
treatment of untested paediatric fevers. Yet, in Benin
and Malawi, diagnostic services seemed less a marker of
access to medicines. In Benin, there were mixed reports
about RDT and ACT availability at peripheral facilities
around this time [9,44], and drug shops without diag-
nostic services are widely used to obtain medicines. In
Malawi, a national facility survey indicated ACT and
other medicines were commonly available at peripheral
clinics that lacked diagnostic services [20]. In Uganda
and Rwanda, in contrast, diagnostic services were morewidely available at this time with microscopy at Ugandan
health centres and RDT at the community level in
Rwanda [44]. In Uganda, however, reported ACT stock-
outs at health centres with microscopy services could
also have impacted its results.
As countries move towards universal test coverage, it
is, therefore, reasonable to expect that expanded access
to testing and care could reduce the strong association
between diagnosis and malaria treatment found in this
analysis. Yet, other factors may still influence this rela-
tionship at the population level even if universal test
coverage is achieved. Other main themes identified in
this study included quality of care, care-seeking behav-
iour and malaria epidemiology, which have also been de-
scribed elsewhere [6,7,25,48,49]. Finally, Rwanda and
Uganda results also suggest that reductions in malaria
treatment associated with testing may be met with in-
creased antibiotic use, which has been documented in
facility-based research from Tanzania [13,15]. Given
strong concerns about irrational antibiotic prescription
habits [50], this finding merits investigation in future
facility-based adherence studies as well.
From a programme perspective, countries could po-
tentially improve population-level results, as exemplified
by Rwanda, largely by expanding access to testing and
care and improving quality case management. Findings
also suggest the impact of diagnostic-scale up on treat-
ment decisions may not be straightforward in routine
programme conditions given such issues as access to for-
mal care, treatment-seeking behaviour or supply stock-
outs. For example, in settings where there is poor access
to formal care or where the informal sector is widely used,
diagnostic services may need to be extended through inte-
grated community case management approaches [51].
This could not only improve access to testing and care,
but also help ensure that non-severe febrile illnesses are at
least as likely to get tested as severe cases. Indeed, diagno-
sis of less severe cases is arguably more informative given
the overlap of initial malaria symptoms with other ill-
nesses [52], the critical need to reduce delays in appropri-
ate fever management [53], and the plausible better test
adherence for less severe patients as hypothesized in case
studies.
This study is the first to use routine national surveys
to examine the effect of diagnostic testing on paediatric
fever treatment at the population level in a standardized
manner across multiple countries and among key sub-
national groups. As part of a mixed-methods approach,
a typology to describe the complex phenomena that
could drive results at the population level is presented,
which draws on similar evaluation methods in health
services research [54]. The inclusion of multiple countries
with contrasting results and common explanatory themes
lends support to the external validity of conclusions
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cation of this typology to other contexts [27]. In fact,
future quantitative research using these datasets could po-
tentially employ these themes to predict the relationship
between testing and treatment at the population level in
other countries or over time as RDT scale-up continues.
This typology could also serve as a standard framework to
assess programmes in routine conditions, and may be par-
ticularly informative for countries without more robust
evidence. Another benefit of DHS analyses is to help iden-
tify countries (e.g., Mozambique) or issues (e.g., malaria
risk) where further facility-based research or programme
attention may be warranted.
There are notable data limitations. First, data in this
analysis are from 2010–2012 and many studied countries
began wide-scale RDT deployment after these surveys
were conducted [44]. Recent research shows improved
test-based treatment practices over time [5,8] and new
methods hold promise to further improve case manage-
ment [55,56]. Countries could show different results in
future analyses, and this assessment could be repeated
once new datasets become available. Second, surveys do
not record a child’s test result and analysis of (in)appro-
priate case management is not possible using these data.
Without the test result, quantitative findings alone are
quite difficult to interpret. The mixed-methods approach
was developed to help understand results but provides
only a set of plausible explanations as a basis for further
quantitative research. Third, analyses of observational
data are prone to residual confounding issues and two
key variables are not directly measured in surveys that
confound the exposure-outcome relationship: illness se-
verity and ‘well-stocked’ facility attendance. This analysis
was limited to DHS datasets that contained specific
proxy variables for these issues, but the relationship
likely remains confounded as highlighted in case studies.
Finally, caregiver recall of medicines given to sick chil-
dren has shown mixed results in studies [57,58]. There
may be worse recall among poor, rural or less educated
mothers [59], which could over-estimate effect differ-
ences across countries if there are systematic differences
in populations with access to testing and treatment.
Conclusions
This paper is the first to quantify the influence of diag-
nostic testing on paediatric fever treatment at the popu-
lation level in a standardized manner across multiple
countries, and is presented as part of a mixed-methods
approach to explain country results. Significant country
variation was found in the effect of diagnostic testing on
paediatric fever treatment at the population-level, and
qualitative results suggest the impact of diagnostic-scale
up on treatment decisions may not be straightforward in
routine programme conditions given contextual issuessuch as access to care, treatment-seeking behaviour or
supply stock-outs. Despite data limitations, quantitative
results could help identify countries (e.g., Mozambique)
or issues (e.g., malaria risk) where facility-based research
or programme attention may be warranted. The mixed-
methods approach brings together population- and facility-
based data, programme documents, research studies, and
expert opinions and could potentially be used to assess
routine programmes across countries or over time to
help fill critical evidence gaps.
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on medicines used by febrile children under five years taken to any
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